Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FBLG logo FBLG
Upturn stock ratingUpturn stock rating
FBLG logo

FibroBiologics, Inc. Common Stock (FBLG)

Upturn stock ratingUpturn stock rating
$0.62
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: FBLG (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10.25

1 Year Target Price $10.25

Analysts Price Target For last 52 week
$10.25 Target price
52w Low $0.53
Current$0.62
52w High $4.41

Analysis of Past Performance

Type Stock
Historic Profit -42.51%
Avg. Invested days 6
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 25.98M USD
Price to earnings Ratio -
1Y Target Price 10.25
Price to earnings Ratio -
1Y Target Price 10.25
Volume (30-day avg) 3
Beta -
52 Weeks Range 0.53 - 4.41
Updated Date 08/29/2025
52 Weeks Range 0.53 - 4.41
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.36

Earnings Date

Report Date 2025-07-31
When -
Estimate -0.12
Actual -0.12

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -88.11%
Return on Equity (TTM) -559.73%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 27910645
Price to Sales(TTM) -
Enterprise Value 27910645
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 41889100
Shares Floating 32066138
Shares Outstanding 41889100
Shares Floating 32066138
Percent Insiders 19.57
Percent Institutions 12.23

ai summary icon Upturn AI SWOT

FibroBiologics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

FibroBiologics, Inc. is a biotechnology company focused on the development of fibroblast-based therapeutic solutions for chronic diseases. Founded with the goal of leveraging the unique properties of fibroblasts, the company has focused on research, development, and clinical applications of its core technologies.

business area logo Core Business Areas

  • Fibroblast-Based Therapies: Development and commercialization of therapies utilizing fibroblasts to treat various diseases.

leadership logo Leadership and Structure

The company has a management team with experience in biotechnology, drug development, and commercialization. The organizational structure is typical of a biotechnology company, with research and development, clinical operations, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Fibroblast-based therapeutic: FibroBiologics is developing fibroblast-based therapies for chronic diseases. As this is under development, market share data is not yet available. Competitors would include other companies working in cell-based therapies and regenerative medicine.

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine and cell-based therapy market is rapidly growing, driven by increasing demand for novel treatments for chronic diseases. The industry is characterized by intense competition and significant investment in research and development.

Positioning

FibroBiologics aims to be a leader in fibroblast-based therapies, leveraging its proprietary technology and expertise. The company's success depends on successful clinical trials and regulatory approvals.

Total Addressable Market (TAM)

The total addressable market for regenerative medicine is substantial, potentially reaching billions of dollars. FibroBiologics is positioned to capture a portion of this market with successful product development and commercialization.

Upturn SWOT Analysis

Strengths

  • Proprietary fibroblast technology
  • Experienced management team
  • Focus on underserved medical needs

Weaknesses

  • Limited clinical data
  • High development costs
  • Dependence on regulatory approvals

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Positive clinical trial results

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Failure of clinical trials

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

Without detailed knowledge of FibroBiologics' specific product pipeline and financial information, a precise competitive landscape assessment is not possible. They will compete with companies in the regenerative medicine field.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is tied to funding, research, and development progress. Specific data is unavailable.

Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates are not readily available.

Recent Initiatives: Recent strategic initiatives may include securing funding, advancing clinical trials, and establishing partnerships.

Summary

FibroBiologics is a biotechnology company in the development stage, focused on fibroblast-based therapies. The company's success hinges on positive clinical trial results and regulatory approvals. As a development stage company, the financial information is dependent on research and development progress and further funding will need to be secured. Key items to watch will be the clinical data and strategic partnerships. The success of their technology will determine their market share.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website (if available)
  • Industry reports
  • General market knowledge

Disclaimers:

This analysis is based on publicly available information and general market knowledge. It is not financial advice. The information provided is not exhaustive and may not be entirely accurate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About FibroBiologics, Inc. Common Stock

Exchange NASDAQ
Headquaters Houston, TX, United States
IPO Launch date 2024-01-31
Founder, Chairperson & CEO Mr. Peter O'Heeron
Sector Healthcare
Industry Biotechnology
Full time employees 13
Full time employees 13

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas.